A perspective on rational designs of a hemagglutinin based universal influenza vaccine

Current Pharmaceutical Design

Volumn 22, Issue 23, 2016, Pages 3547-3554

  Van, Thanh D ^a,b   Tran, Nhut ^a,b   Le, Ly ^a,b   Eisenhaber, Frank ^c,d,e  

^a INSTITUTE FOR COMPUTATIONAL SCIENCE AND TECHNOLOGY   (Viet Nam)

^b INTERNATIONAL UNIVERSITY   (Viet Nam)

^c BIOINFORMATICS INSTITUTE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Antiviral immunity; Hemagglutinin (HA); Influenza virus; Universal influenza vaccine

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE;

ADAPTIVE IMMUNITY; CELLULAR IMMUNITY; ENDOCYTOSIS; HUMAN; HUMORAL IMMUNITY; INFLUENZA; INNATE IMMUNITY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; VIRUS ATTACHMENT;

EID: 84978224846     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160419144352     Document Type: Review

References (86)

1. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull History Med 2002; 76(1): 105-15.
2. Isakova-Sivak I, de Jonge J, Smolonogina T, et al. Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus. PloS One 2014; 9(7): e102339.
3. Koelle K, Cobey S, Grenfell B, Pascual M. Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. Science 2006; 314(5807): 1898-903.
4. Sonnberg S, Webby RJ, Webster RG. Natural history of highly pathogenic avian influenza H5N1. Virus Res 2013; 178(1): 63-77.
5. Mummert A, Weiss H, Long LP, Amigo JM, Wan XF. A perspective on multiple waves of influenza pandemics. PloS One 2013; 8(4): e60343.
6. Han J, Wang L, Liu J, et al. Cocirculation of three hemagglutinin and two neuraminidase subtypes of avian influenza viruses in Huzhou, China, April 2013: implication for the origin of the novel H7N9 virus. J Virol 2014; 88(11): 6506-11.
7. Lee RT, Gunalan V, Van TD, Le LT, Eisenhaber F, Maurer-Stroh S. A new piece in the puzzle of the novel avian-origin influenza A (H7N9) virus. Biol Direct 2013; 8: 26.
8. Ampofo WK, Azziz-Baumgartner E, Bashir U, et al. Strengthening the influenza vaccine virus selection and development process: report of the 3rd WHO informal consultation for improving influenza vaccine virus selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014. Vaccine 2015; 33(36): 4368-82.
9. Nelson MI, Wentworth DE, Culhane MR, et al. Introductions and evolution of human-origin seasonal influenza a viruses in multinational swine populations. J Virol 2014; 88(17): 10110-9.
10. Tran N, Van T, Nguyen H, Le L. Identification of novel compounds against an R294K substitution of influenza A (H7N9) virus using ensemble based drug virtual screening. Int J Med Sci 2015; 12(2): 163-76.
11. Krammer F. Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Biotechnol J 2015; 10(5): 690-701.
12. Bouvier NM, Palese P. The biology of influenza viruses. Vaccine 2008; 26 (Suppl 4): D49-53.
13. Bao Y, Bolotov P, Dernovoy D, et al. The influenza virus resource at the national center for biotechnology information. J Virol 2008; 82(2): 596-601.
14. Mallajosyula VV, Citron M, Ferrara F, et al. Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 Subtype. Front Immunol 2015; 6: 329.
15. Gravel C, Li C, Wang J, et al. Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays. J Vis Exp 2011; (50)pii: 2784.
16. Tria F, Pompei S, Loreto V. Dynamically correlated mutations drive human Influenza A evolution. Sci Rep 2013; 3: 2705.
17. Jeong CS, Kim D. Reliable and robust detection of coevolving protein residues. Prot Eng Des Select 2012; 25(11): 705-13.
18. Kuznetsov V, Lee HK, Maurer-Stroh S, et al. How bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public health. Health Inf Sci Syst 2013; 1: 2.
19. Wu G, Yan SM. Mutation trend of hemagglutinin of influenza A virus: a review from a computational mutation viewpoint. Acta Pharmacol Sin 2006; 27(5): 513-26.
20. Neverov AD, Kryazhimskiy S, Plotkin JB, Bazykin GA. Coordinated evolution of influenza a surface proteins. PLoS Genet 2015; 11(8): e1005404.
21. Maurer-Stroh S, Li Y, Bastien N, et al. Potential human adaptation mutation of influenza A(H5N1) virus, Canada. Emerg Infect Dis 2014; 20(9): 1580-2.
22. Lee RT, Santos CL, de Paiva TM, et al. All that glitters is not gold-- founder effects complicate associations of flu mutations to disease severity. Virology J 2010; 7: 297.
23. Maurer-Stroh S, Paing SS, Lee RT, Eisenhaber F. Sporadic human cases of swine-origin influenza before 2009 share the Sa epitope. Cell Cycle 2010; 9(18): 3826-8.
24. Maurer-Stroh S, Lee RT, Eisenhaber F, Cui L, Phuah SP, Lin RT. A new common mutation in the hemagglutinin of the 2009 (H1N1) influenza A virus. PLoS Curr 2010; 2: RRN1162.
25. Shriver Z, Trevejo JM, Sasisekharan R. Antibody-based strategies to prevent and treat influenza. Front Immunol 2015; 6: 315.
26. Throsby M, van den Brink E, Jongeneelen M, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PloS One 2008; 3(12): e3942.
27. Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324(5924): 246-51.
28. Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16(3): 265-73.
29. Oh HL, Akerstrom S, Shen S, et al. An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses. J Virol 2010; 84(16): 8275-86.
30. Dreyfus C, Laursen NS, Kwaks T, et al. Highly conserved protective epitopes on influenza B viruses. Science 2012; 337(6100): 1343-8.
31. Friesen RH, Lee PS, Stoop EJ, et al. A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci USA 2014; 111(1): 445-50.
32. Ekiert DC, Friesen RH, Bhabha G, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011; 333(6044): 843-50.
33. Ekiert DC, Kashyap AK, Steel J, et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 2012; 489(7417): 526-32.
34. Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333(6044): 850-6.
35. Lee PS, Ohshima N, Stanfield RL, et al. Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus. Nat Commun 2014; 5: 3614.
36. Kashyap AK, Steel J, Rubrum A, et al. Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor- based libraries. PLoS Pathog 2010; 6(7): e1000990.
37. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe JE Jr. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 2011; 85(20): 10905-8.
38. Shao H, Ye J, Vincent AL, et al. A novel monoclonal antibody effective against lethal challenge with swine-lineage and 2009 pandemic H1N1 influenza viruses in mice. Virology 2011; 417(2): 379-84.
39. Wu Y, Cho M, Shore D, et al. A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus. Nat Commun 2015; 6: 7708.
40. Steel J, Lowen AC, Wang TT, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 2010; 1(1).
41. Kanekiyo M, Wei CJ, Yassine HM, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013; 499(7456): 102-6.
42. Wu CY, Yeh YC, Chan JT, et al. A VLP vaccine induces broadspectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus. PloS One 2012; 7(8): e42363.
43. Kang SM, Kim MC, Compans RW. Virus-like particles as universal influenza vaccines. Exp Rev Vaccines 2012; 11(8): 995-1007.
44. Schwartzman LM, Cathcart AL, Pujanauski LM, Qi L, Kash JC, Taubenberger JK. An intranasal virus-like particle vaccine broadly protects mice from multiple subtypes of influenza a virus. mBio 2015; 6(4): e01044.
45. Tong S, Zhu X, Li Y, Shi M, Zhang J, Bourgeois M, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog 2013; 9(10): e1003657.
46. Gamblin SJ, Haire LF, Russell RJ, et al. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 2004; 303(5665): 1838-42.
47. Liu J, Stevens DJ, Haire LF, et al. Structures of receptor complexes formed by hemagglutinins from the Asian Influenza pandemic of 1957. Proc Natl Acad Sci USA 2009; 106(40): 17175-80.
48. Ciampor F, Bayley PM, Nermut MV, Hirst EM, Sugrue RJ, Hay AJ. Evidence that the amantadine-induced, M2-mediated conversion of influenza A virus hemagglutinin to the low pH conformation occurs in an acidic trans Golgi compartment. Virology 1992; 188(1): 14-24.
49. Maurer-Stroh S, Lee RT, Gunalan V, Eisenhaber F. The highly pathogenic H7N3 avian influenza strain from July 2012 in Mexico acquired an extended cleavage site through recombination with host 28S rRNA. Virol J 2013; 10: 139.
50. Grambas S, Hay AJ. Maturation of influenza A virus hemagglutinin-- estimates of the pH encountered during transport and its regulation by the M2 protein. Virology 1992; 190(1): 11-8.
51. Betakova T, Ciampor F, Hay AJ. Influence of residue 44 on the activity of the M2 proton channel of influenza A virus. J General Virol 2005; 86(Pt 1): 181-4.
52. van de Sandt CE, Kreijtz JH, Rimmelzwaan GF. Evasion of influenza A viruses from innate and adaptive immune responses. Viruses 2012; 4(9): 1438-76.
53. Stifter SA, Bhattacharyya N, Pillay R, et al. Functional Interplay between Type I and II Interferons Is Essential to Limit Influenza A Virus-Induced Tissue Inflammation. PLoS Pathog 2016; 12(1): e1005378.
54. Yu D, Zhao M, Dong L, et al. Design and evaluation of novel interferon lambda analogs with enhanced antiviral activity and improved drug attributes. Drug Des Develop Ther 2016; 10: 163-82.
55. Wu W, Zhang W, Duggan ES, Booth JL, Zou MH, Metcalf JP. RIG-I and TLR3 are both required for maximum interferon induction by influenza virus in human lung alveolar epithelial cells. Virology 2015; 482: 181-8.
56. Fernandez MV, Miller E, Krammer F, Gopal R, Greenbaum BD, Bhardwaj N. Ion efflux and influenza infection trigger NLRP3 inflammasome signaling in human dendritic cells. J Leukocyte Biol 2015.
57. Carta S, La Frazia S, Donatelli I, Puzelli S, Rossi A, Santoro MG. Prostaglandin A1 inhibits avian influenza virus replication at a postentry level: Effect on virus protein synthesis and NF-kappaB activity. Prostaglandins Leukot Essent Fatty Acids 2014; 91(6): 311-23.
58. Wei D, Huang ZH, Zhang RH, et al. Roles of p38 MAPK in the regulation of the inflammatory response to swine influenza virusinduced acute lung injury in mice. Acta Virol 2014; 58(4): 374-9.
59. James SJ, Jiao H, Teh HY, et al. MAPK phosphatase 5 expression induced by influenza and other RNA virus infection negatively regulates IRF3 activation and type I interferon response. Cell Rep 2015.
60. Tsai SY, Segovia JA, Chang TH, et al. DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation during influenza A virus infection: role of DDX21-TRIF-TLR4-MyD88 pathway. PLoS Pathog 2014; 10(1): e1003848.
61. Makela SM, Osterlund P, Westenius V, et al. RIG-I signaling is essential for influenza B virus-induced rapid interferon gene expression. J Virol 2015; 89(23): 12014-25.
62. Shevlin E, Miggin SM. The TIR-domain containing adaptor TRAM is required for TLR7 mediated RANTES production. PloS One 2014; 9(9): e107141.
63. Richard AL, Siegel SJ, Erikson J, Weiser JN. TLR2 signaling decreases transmission of Streptococcus pneumoniae by limiting bacterial shedding in an infant mouse Influenza A co-infection model. PLoS Pathog 2014; 10(8): e1004339.
64. Anchisi S, Guerra J, Mottet-Osman G, Garcin D. Mismatches in the influenza A virus RNA panhandle prevent retinoic acid-inducible gene I (RIG-I) sensing by impairing RNA/RIG-I complex formation. J Virol 2015; 90(1): 586-90.
65. Pulendran B, Maddur MS. Innate immune sensing and response to influenza. Curr Top Microbiol Immunol 2015; 386: 23-71.
66. Haye K, Burmakina S, Moran T, Garcia-Sastre A, Fernandez-Sesma A. The NS1 protein of a human influenza virus inhibits type I interferon production and the induction of antiviral responses in primary human dendritic and respiratory epithelial cells. J Virol 2009; 83(13): 6849-62.
67. Matthaei M, Budt M, Wolff T. Highly pathogenic H5N1 influenza A virus strains provoke heterogeneous IFN-alpha/beta responses that distinctively affect viral propagation in human cells. PloS One 2013; 8(2): e56659.
68. Noah DL, Twu KY, Krug RM. Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3' end processing of cellular pre-mRNAS. Virology 2003; 307(2): 386-95.
69. Kuo RL, Krug RM. Influenza a virus polymerase is an integral component of the CPSF30-NS1A protein complex in infected cells. J Virol 2009; 83(4): 1611-6.
70. Ayllon J, Domingues P, Rajsbaum R, et al. A single amino acid substitution in the novel H7N9 influenza A virus NS1 protein increases CPSF30 binding and virulence. J Virol 2014; 88(20): 12146-51.
71. Kosik I, Praznovska M, Kosikova M, et al. The ubiquitination of the influenza A virus PB1-F2 protein is crucial for its biological function. PloS One 2015; 10(4): e0118477.
72. Schmolke M, Manicassamy B, Pena L, et al. Differential contribution of PB1-F2 to the virulence of highly pathogenic H5N1 influenza A virus in mammalian and avian species. PLoS Pathog 2011; 7(8): e1002186.
73. Varga ZT, Grant A, Manicassamy B, Palese P. Influenza virus protein PB1-F2 inhibits the induction of type I interferon by binding to MAVS and decreasing mitochondrial membrane potential. J Virol 2012; 86(16): 8359-66.
74. He W, Mullarkey CE, Duty JA, Moran TM, Palese P, Miller MS. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones. J Virol 2015; 89(7): 3610-8.
75. Brandenburg B, Koudstaal W, Goudsmit J, et al. Mechanisms of hemagglutinin targeted influenza virus neutralization. PloS One 2013; 8(12): e80034.
76. Atsmon J K-IE, Shaikevich D, Singer Y, Volokhov I, Haim KY, Ben-Yedidia T. Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine. J Clin Immunol 2012; 32(3): 595-603.
77. Li R, Chowdhury MY, Kim JH, et al. Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes. Veterinary Microbiol 2015; 179(3-4): 250-63.
78. Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. New Engl J Med 2011; 365(15): 1406-16.
79. Vesikari J, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011; 365(15): 1406-16.
80. Corti A, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 2013; 31: p. 705-42.
81. Krammer F, Pica N, Hai R, et al. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol Release 2013; 87(12): p. 6542-50.
82. Ekiert DC WI. Antibody recognition of a highly conserved influenza virus epitope: implications for universal prevention and therapy. Science 2009; 324(5924): 246-51.
83. Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16(3): 265-73.
84. Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 2010; 6(2): e1000796.
85. Yassine HM, Boyington JC, McTamney PM, et al. Hemagglutininstem nanoparticles generate heterosubtypic influenza protection. Nat Med 2015; 21(9): 1065-70.
86. Impagliazzo A, Milder F, Kuipers H, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 2015; 349(6254): 1301-6.